BioPharma Dive10h
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...
Diabetes patients worry about insulin shortages as Ozempic use skyrockets
The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
raising concerns among investors that demand might be cooling for the products. Those market dynamics will again be in ...
Ozempic, Wegovy sales inject wealth into Novo Nordisk home country of Denmark
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Zacks.com on MSN13h
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is expected to beat estimates when it reports third-quarter 2024 results on Nov. 6, before the opening bell.
FiercePharma4d
Novo Nordisk hit with FDA write-up over production issues at critical semaglutide plant
Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...
Novo Nordisk (0QIU) Receives a Buy from Deutsche Bank
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with ...
$35 insulin: Who in the US benefits?
Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a ...
FierceBiotech14h
Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)
UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The ...